Title |
The clinical and functional significance of c-Met in breast cancer: a review
|
---|---|
Published in |
Breast Cancer Research, April 2015
|
DOI | 10.1186/s13058-015-0547-6 |
Pubmed ID | |
Authors |
Colan M Ho-Yen, J Louise Jones, Stephanie Kermorgant |
Abstract |
c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor is regarded as a novel therapeutic target. In breast cancer there is a need to develop new treatments, particularly for the aggressive subtypes such as triple-negative and basal-like cancer, which currently lack targeted therapy. Over the last two decades, much has been learnt about the functional role of c-Met signalling in different models of breast development and cancer. This work has been complemented by clinical studies, establishing the prognostic significance of c-Met in tissue samples of breast cancer. While the clinical trials of anti-c-Met therapy in advanced breast cancer progress, there is a need to review the existing evidence so that the potential of these treatments can be better appreciated. The aim of this article is to examine the role of HGF/c-Met signalling in in vitro and in vivo models of breast cancer, to describe the mechanisms of aberrant c-Met signalling in human tissues, and to give a brief overview of the anti-c-Met therapies currently being evaluated in breast cancer patients. We will show that the HGF/c-Met pathway is associated with breast cancer progression and suggest that there is a firm basis for continued development of anti-c-Met treatment, particularly for patients with basal-like and triple-negative breast cancer. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Austria | 1 | <1% |
Unknown | 154 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 40 | 26% |
Researcher | 19 | 12% |
Student > Bachelor | 18 | 12% |
Student > Master | 15 | 10% |
Student > Doctoral Student | 10 | 6% |
Other | 22 | 14% |
Unknown | 32 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 37 | 24% |
Agricultural and Biological Sciences | 34 | 22% |
Medicine and Dentistry | 24 | 15% |
Chemistry | 6 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
Other | 14 | 9% |
Unknown | 37 | 24% |